Abstract
Objective
The aim of the study was to explore the effects of the same target (si-10) on lung cancer cells with different expression levels of cyclooxygenase-2 (COX-2) protein by RNAi and malignant proliferation of these cells.
Methods
COX-2 was selected as the target and one siRNA expression vector with the best effect was selected and thought as the subject from three COX-2 siRNA expression vectors with human U6 promoter. The siRNA expression vector (psi-10) and the vacant vector (pEGFP) were transfected into these cells with different COX-2 expression states (801D, A549 and LTEP-A2) with lipofectamine respectively and the transfected cell strains were constructed. The change of COX-2 expression levels was examined by Western blot and RT-PCR. The effects on the proliferation of lung cancer cells were studied by cell growth curve and clonogenic assay.
Results
The siRNA and U6 promoter were validated by PCR, restriction endonucleases identification and DNA sequencing and BLAST alignment and cloned into the pEGFP vector. The cell strains transfected that 801D was used as maternal line were named as 801D-p and 801D-10 respectively. The cell strains transfected that A549 was used as maternal line were named as A549-p and A549-10 respectively. The cell strains transfected that LTEP-A2 was used as maternal line were named as LTEP-A2-p and LTEP-A2-10 respectively. These cells transfected pEGFP (801D-p, A549-p and LTEP-A2-p) had the expression of GFP and 801D-10, A549-10 and LTEP-A2-10 cells had not in 24, 48 and 72 hours after transfected. The results of RT-PCR and Western blot showed the siRNA expression vector produced marked effects in two cells (A549 and LTEP-A2) expressing COX-2 and the expression of COX-2 was inhibited. But the inhibited effects were different and the expression of COX-2 was more inhibited obviously in LTEP-A2 cells than in A549 cells though the expression of COX-2 was also inhibited obviously in A549 cells. In contract to their maternal line, the levels of COX-2 mRNA of LTEP-A2-10 and A549-10 cells reduced 64.2% and 61.2% respectively; the levels of COX-2 protein reduced 60.2% and 56.2% respectively. But the levels of COX-2 mRNA and protein had not change in 801D cells not expressing COX-2. The results of cell growth curve and clonogenic assay showed the growth of LTEP-A2-10 cells slowed and the clonal formation rate reduced and the size of the colonies became small; the growth of A549-10 cells showed slow and more obviously in the cell growth curve especially. But the growth of 801D-10 cells had not obvious change.
Conclusion
The si-10 target of COX-2 has different inhibition effects on lung cancer cells with different COX-2 expression levels and the different inhibition effects have different effects on cells malignant proliferation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Shi H, Xu JM, Hu NZ, et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol, 2003, 9: 1421–1426.
Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol, 2002, 190: 279–286.
Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol, 2003, 37: 28–33.
Upadhyay R, Jain M, Kumar S, et al. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat Res, 2009, 663: 52–59.
Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate and lung. Inflammopharmacology, 2009, 17: 55–67.
Gao YW, Chen YX, Wang ZM, et al. Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma. Digestion, 2009, 79: 169–176.
Husvik C, Khuu C, Bryne M, et al. PGE2 production in oral cancer cell lines is COX-2-dependent. J Dent Res, 2009, 88: 164–169.
Li F, Ren GS, Li HY, et al. A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol), 2009, 21: 302–305.
Zafirellis K, Agrogiannis G, Zachaki A. Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer. APMIS, 2008, 116: 912–922.
Xia XG, Zhou H, Ding H, et al. An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res, 2003, 31: e100.
Chen J, Bai CX, Zhang M. Application of RNA interference in mammalian cells. Prog Biochem Biophys (Chinese), 2003, 30: 650–654.
Li WY, Wang H, Lai BT, et al. Effects of RNA interference of COX-2 gene expression on malignant proliferation of A549 cells in vitro. Chin J Oncol (Chinese), 2007, 29: 904–908.
Dohadwala M, Luo J, Zhu L, et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion in mediated by CD44. J Biol Chem, 2001, 276: 20809–20812.
Petkova DK, Clelland C, Ronan J, et al. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir Med, 2004, 98: 164–172.
Zhuo WL, Wang Y, Chen ZT. Inhibitory effects of shRNA targeting layilin on adhesion and invasion behavior of human lung adenocarcinoma A549 cells induced by hyaluronan in vitro. Chin J Lung Cancer (Chinese), 2006, 9: 236–240.
Li G, Li XP, Liu X, et al. Inhibition of EBV-encoded LMP-1 by DNA-based RNA interference affects metastatic ability of nasopharyngeal carcinoma cells. Chin J Oncol (Chinese), 2006, 28: 724–727.
Xu XH, Hu GQ, Li S, et al. Expression of cyclooxygenase-2 in nasopharyngeal carcinoma and its relation to angiogenesis and prognosis. Chinese-German J Clin Oncol, 2006, 5: 104–107.
Goulart Filho JA, Nonaka CF, da Costa Miguel MC, et al. Immunoex-pression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. Am J Otolaryngol, 2009, 30: 89–94.
Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis, 2009, 30: 377–386.
Rodriguez NI, Hoots WK, Koshkina NV, et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol, 2008, 30: 507–512.
Xiang MZ, Jiang YG, Wang HC, et al. Effects of reducing FasL expression on T cell apoptosis in lung cancer cell line H460 via siRNA technology. Chin J Lung Cancer (Chinese), 2007, 10: 5–8.
Czembirek C, Eder-Czembirek C, Erovic BM, et al. The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells. Strahlenther Onkol, 2009, 185: 310–317.
Maussang D, Langemeijer E, Fitzsimons CP, et al. The human cyto-megalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res, 2009, 69: 2861–2869.
Oba M, Miwa K, Fujimura T, et al. A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats. Cancer, 2009, 115: 454–464.
Chang ET, Cronin-Fenton DP, Friis S, et al. Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomarkers Prev, 2010, 19: 59–64.
Van Dyke AL, Cote ML, Prysak GM, et al. COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis, 2008, 29: 1781–1787.
Charames GS, Bapat B. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol, 2006, 28: 543–549.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, W., Wang, H., Lai, B. et al. The effects of the same target on malignant proliferation of human lung cancer cells with different expression levels of COX-2 protein. Chin. -Ger. J. Clin. Oncol. 9, 125–132 (2010). https://doi.org/10.1007/s10330-009-0144-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-009-0144-1